Welcome to CDC Stacks | Resolution of Novel Human Papillomavirus–induced Warts after HPV Vaccination - 21526 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Resolution of Novel Human Papillomavirus–induced Warts after HPV Vaccination
  • Published Date:
    Jan 2014
  • Source:
    Emerg Infect Dis. 20(1):142-145.
Filetype[PDF - 365.66 KB]


Details:
No Related Documents.
You May Also Like:
  1. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels
    Personal Author:
    Jemal, Ahmedin; Simard, Edgar P.; Dorell, Christina; Noone, Anne-Michelle; Markowitz, Lauri E.; Kohler, Betsy; Eheman, Christie; Saraiya, Mona; Bandi, Priti; Saslow, Debbie; Cronin, Kathleen A.; Watson, Meg; Schiffman, Mark; Henley, S. Jane; Schymura, Maria J.; Anderson, Robert N.; Yankey, David; Edwards, Brenda K.;
    Published:
    Jan 07 2013
    Source:
    J Natl Cancer Inst. 2013; 105(3):175-201.
    Description:
    Background : The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide update...
    File Type:
    Filetype[PDF - 5.10 MB]
  2. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
    Personal Author:
    Cameron, Ross L.; Kavanagh, Kimberley; Pan, Jiafeng; Love, John; Cuschieri, Kate; Robertson, Chris; Ahmed, Syed; Palmer, Timothy; Pollock, Kevin G.J.;
    Published:
    Jan 2016
    Source:
    Emerg Infect Dis. 22(1):56-64.
    Description:
    In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccinat...
    File Type:
    Filetype[PDF - 527.22 KB]
  3. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(20):626-9.
    Description:
    On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licens...
    Status:
    current
    File Type:
    Filetype[PDF]
  4. Sexually Related Behaviors as Predictors of HPV Vaccination Among Young Rural Women
    Personal Author:
    Mills, Laurel A.; Vanderpool, Robin C.; Crosby, Richard A.;
    Published:
    Dec 02 2011
    Source:
    J Womens Health (Larchmt). 20(12):1909-1915.
    Description:
    Purpose : To explore whether sexually related behaviors predict refusal of the human papillomavirus (HPV) vaccine among a sample of women aged 18–26 in Appalachian Kentucky. : Methods : Using a convenience sample, young women attending health clini...
    File Type:
    Filetype[PDF - 186.33 KB]
  5. HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence
    Personal Author:
    Weinbaum, Cindy M.; Cano, Maria;
    Published:
    Aug 19 2015
    Source:
    EBioMedicine. 2(9):1014-1015.
    File Type:
    Filetype[PDF - 147.88 KB]